OMER
Omeros Corporation
NASDAQ · Healthcare · Biotechnology · US
$18.95
−0.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 38.4M | — | — | — | — |
| Cost of Revenue | 1.6M | — | — | — | — |
| Gross Profit | 36.8M | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 62.4M | 81.3M | 119.5M | 114.9M | 112.7M |
| SG&A Expense | 47.3M | 41.5M | 49.7M | 49.7M | 50.7M |
| General & Admin Expense | 47.3M | 41.5M | 49.7M | 49.7M | 50.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 109.6M | 122.8M | 169.3M | 164.5M | 163.4M |
| Cost and Expenses | 111.2M | 122.8M | 169.3M | 164.5M | 163.4M |
| Operating Income (EBIT) | (72.8M) | (122.8M) | (169.3M) | (164.5M) | (163.4M) |
| Non-Operating | |||||
| Interest Income | 15.4M | 5.1M | 11.3M | 16.3M | 4.1M |
| Interest Expense | 22.2M | — | 24.7M | 30.8M | 22.7M |
| Net Interest Income | (6.8M) | 5.1M | (13.4M) | (14.5M) | (18.6M) |
| Other Non-Op Income/Expense | 191.5M | 120.0M | (13.4M) | (10.4M) | (18.6M) |
| Non-Operating Income (excl Interest) | (204.9M) | (120.0M) | (11.3M) | (20.5M) | (4.1M) |
| EBT (Pre-Tax Income) | 118.6M | (2.8M) | (182.6M) | (174.9M) | (182.0M) |
| Income Tax Expense | 2.1M | 2.0M | — | — | — |
| Bottom Line | |||||
| Net Income | 124.8M | (3.4M) | (156.8M) | (117.8M) | 47.4M |
| Earnings from Cont. Ops | 116.5M | (4.8M) | (182.6M) | (174.9M) | (182.0M) |
| Earnings from Discont. Ops | 8.3M | 1.5M | 25.8M | 57.1M | 229.4M |
| Bottom Line Net Income | 124.8M | (3.4M) | (156.8M) | (117.8M) | 47.4M |
| Per Share | |||||
| Basic EPS | $1.91 | ($0.05) | ($2.70) | ($1.88) | $0.46 |
| Diluted EPS | $1.72 | ($0.05) | ($2.70) | ($1.88) | $0.46 |
| Revenue Per Share | $0.53 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 72.1M | 63.5M | 58.2M | 62.7M | 62.7M |
| Diluted Shares Outstanding | 89.6M | 63.5M | 58.2M | 62.7M | 62.7M |
| Profitability Metrics | |||||
| EBITDA | 136.2M | (1.8M) | (157.0M) | (143.2M) | (158.4M) |
| D&A | 4.0M | 964.0K | 950.0K | 920.0K | 952.0K |
| EBIT | 132.1M | (2.8M) | (158.0M) | (144.1M) | (159.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026